论文部分内容阅读
目的：研究肝动脉灌注LAK细胞／白介素Ⅱ，联合化疗栓塞治疗原发性肝癌的价值。方法：肝动脉灌注LAK细胞／白介素Ⅱ，联合化疗栓塞治疗原发性肝癌17例（观察组），与单纯肝动脉化疗栓塞治疗原发性肝癌17例（对照组）。对两组病例的疗效及生存期进行对比观察。结果：观察组总有效率与1年生存率均较对照组显著提高（P＜0.01）;观察组2年生存率也明显高于对照组（P＜0.05）。结论：肝动脉灌注的LAK细胞/白介素Ⅱ与某些化疗药物具有协同杀伤肿瘤细胞的作用，LAK细胞／白介素Ⅱ又可作用于机体免疫系统，显著改善或重建机体免疫功能，克服化疗栓塞使患者免疫力更加低下的副作用，从而提高疗效，延长患者生存期。肝动脉灌注LAK细胞／白介素Ⅱ联合化疗栓塞，是原发性肝癌很有价值的治疗方法。
OBJECTIVE: To study the value of hepatic artery perfusion of LAK cells/interleukin II in combination with chemoembolization for primary hepatic carcinoma. Methods: Hepatic artery perfusion of LAK cells / interleukin II, combined with chemotherapy embolization treatment of primary liver cancer in 17 cases (observation group), and simple hepatic arterial chemoembolization in the treatment of primary liver cancer in 17 cases (control group). The efficacy and survival of the two groups were compared. Results: The total effective rate and 1-year survival rate in the observation group were significantly higher than those in the control group (P<0.01). The 2-year survival rate in the observation group was also significantly higher than that in the control group (P<0.05). Conclusions: LAK/IL-2 perfused with hepatic arteries can synergistically kill tumor cells with certain chemotherapeutic agents. LAK/IL-2 can also act on the immune system, significantly improve or rebuild immune function, and overcome the chemoembolization of patients. Less side effects of immunity, thereby improving the efficacy and prolonging the survival of patients. Hepatic artery perfusion of LAK cells/interleukin II combined with chemoembolization is a valuable treatment for primary liver cancer.